Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling
| Autor: | Minjuan Feng, Dongge Cai, Hongli Sun, Yan Zhao, Xiaogui Zhao, Jinyan Zhao, Qiuyuan Wan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
endocrine system diseases Endocrinology Diabetes and Metabolism Endometrium Phosphatidylinositol 3-Kinases 03 medical and health sciences 0302 clinical medicine Endocrinology Carcinoma Humans Medicine Protein kinase B PI3K/AKT/mTOR pathway Cell Proliferation Cell growth business.industry TOR Serine-Threonine Kinases Endometrial cancer RPTOR nutritional and metabolic diseases Obstetrics and Gynecology Middle Aged medicine.disease Metformin Endometrial Neoplasms 030104 developmental biology 030220 oncology & carcinogenesis Cancer research Immunohistochemistry Female business Proto-Oncogene Proteins c-akt Signal Transduction medicine.drug |
| Zdroj: | Gynecological Endocrinology. 34:428-432 |
| ISSN: | 1473-0766 0951-3590 |
| Popis: | Metformin recently gained traction as potential anti-endometrial cancer agent for its new applications. However, the underlying mechanisms of the anti-cancer effect of metformin in the endometrial cancer have not yet been fully elucidated. Sixty-five patients diagnosed as endometrial carcinoma were grouped into (n = 33) and non-treatment mixed (n = 32) for analysis. Thirty healthy donors were recruited as controls. We attempt to investigate the effect of metformin on Ki-67, PI3K, p-AKT, p-S6K1, and p-4EBP1 staining in human endometrial cancer by immunohistochemical staining. We found that increased Ki-67 expression in women with endometrial cancer, which were reversed by conventional anti-diabetic doses of metformin in present work. In parallel, the reduced PI3K, p-AKT, p-S6K1, and p-4EBP1 staining induced by metformin appeared to play an important role for the anti-proliferative effects of metformin in endometrial cancer patients. Metformin significantly decreased proliferation in human endometrial cancer may by inhibiting PI3K/AKT/mTOR signaling. Our present results add to the growing body of evidence supporting metformin as a potential anti-cancer agent in endometrial cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|